Allogene Therapeutics has reported a patient death tied to its anti-CD52 monoclonal antibody used for lymphodepletion in its ...

After the surprise departure of longtime CEO Lars Fruergaard Jørgensen in May, Danish pharma giant Novo Nordisk didn’t take ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

D Molecular Therapeutics has posted 60-week data on a gene therapy, providing evidence of durability in diabetic macular edema and sending its stock up more than 40% in premarket trading.

A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung tumors, ...

AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis (UC) after a phase 2 study revealed ...

After taking on the title of president earlier this year, Dexcom’s Jake Leach will be stepping into the role of CEO at the ...

NXP800, a GCN2 kinase activator, has been on shaky ground since a data drop in November revealed a lack of efficacy. Seeking to improve outcomes, Nuvectis turned its attention to a new cohort of ...

Last week, Australian life sciences venture capital firm Brandon Capital closed its largest fund yet, raising A$439 million ...

AbbVie has reportedly added Gilgamesh Pharmaceuticals to its shopping list. | AbbVie has reportedly added Gilgamesh ...

Maryland-based biotech NextCure is looking for partners to advance a candidate for the currently incurable rare disease ...

Medical AI company Cardiosense has claimed FDA clearance for its CardioTag device, a wearable sensor that provides a ...